文献速递MDS 与骨髓增殖性肿瘤白血病

TP53突变定义复杂核型新发与治疗相关MDS/AML中的独特亚组

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
PubMed 文献 · Blood Adv · 2022-01-01

该研究纳入多学术机构299例复杂核型(CK)的AML和MDS患者,评估其临床病理特征与结局。287例(96%)检出突变,TP53突变最常见(247例,83%)。TP53突变在治疗相关病例中频率更高(P = .008),在治疗相关组内强烈预测更差结局(P = .0017)。多因素分析显示多打击TP53突变是最强的不良预后预测因子,而AML与MDS诊断或治疗相关性均未独立影响总生存。

要点

  • 复杂核型MDS/AML中TP53突变率高达83%,治疗相关病例频率更高(P = .008)。
  • 治疗相关组内TP53突变强烈预测更差生存(P = .0017),多打击TP53为最强不良预后因子。
  • AML与MDS诊断分类或循环原始细胞≥1%与否对生存无显著影响(P = .96;P = .52)。

核心结论

  • 在复杂核型MDS和AML中,TP53突变(尤其多打击TP53突变)定义了一个同质性侵袭性疾病,与就诊时原始细胞计数或治疗相关性无关。
  • 当前将这些病例分为不同疾病类别人为地分离了单一生物学疾病实体。

研究设计与样本

  • 从多个学术机构收集299例复杂核型AML和MDS患者,评估其临床病理特征与结局。

主要发现

  • 287例(96%)检出突变,TP53突变最常见(247例,83%)。
  • 治疗相关病例中TP53突变频率更高(P = .008),治疗相关患者较新发患者总生存有更差趋势(P = .08)。
  • 治疗相关组内,TP53突变强烈预测更差结局(P = .0017)。
  • 复杂核型患者按AML vs MDS分类(P = .96)或循环原始细胞≥1%有无(P = .52)生存无差异。
  • TP53突变患者较无TP53突变的复杂核型患者年龄更大(P = .06)、血红蛋白水平更低(P = .004)、骨髓原始细胞计数更低(P = .02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A subset of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) show complex karyotype (CK), and these cases include a relatively high proportion of cases of therapy-related myeloid neoplasms and TP53 mutations. We aimed to evaluate the clinicopathologic features of outcome of 299 AML and MDS patients with CK collected from multiple academic institutions. Mutations were present in 287 patients (96%), and the most common mutation detected was in TP53 gene (247, 83%). A higher frequency of TP53 mutations was present in therapy-related cases (P = .008), with a trend for worse overall survival (OS) in therapy-related patients as compared with de novo disease (P = .08) and within the therapy-related group; the presence of TP53 mutation strongly predicted for worse outcome (P = .0017). However, there was no difference in survival between CK patients based on categorization of AML vs MDS (P = .96) or presence of absence of circulating blasts ≥1% (P = .52). TP53-mutated patients presented with older age (P = .06) and lower hemoglobin levels (P = .004) and marrow blast counts (P = .02) compared with those with CK lacking TP53 mutation. Multivariable analysis identified presence of multihit TP53 mutation as strongest predictor of worse outcome, whereas neither a diagnosis of AML vs MDS nor therapy-relatedness independently influenced OS. Our findings suggest that among patients with MDS and AML, the presence of TP53 mutation (in particular multihit TP53 mutation) in the context of CK identifies a homogeneously aggressive disease, irrespective of the blast count at presentation or therapy-relatedness. The current classification of these cases into different disease categories artificially separates a single biologic disease entity.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Weinberg OK, Siddon A, Madanat YF, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022. PMID: 35073573. doi:10.1182/bloodadvances.2021006239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。